MEDI 23-Multivalent muscarinic antagonists for the treatment of overactive bladder (OAB)

被引：0
|
作者：
Hughes, Adam D. [1 ]
Chin, Kay H. [2 ]
Hegde, Sharath S. [3 ]
Husfeld, Craig O. [1 ]
Jasper, Jeffrey R. [2 ]
Ji, Yuhua [1 ]
King, Kristin E. [2 ]
Lee, Tae Weon [2 ]
Li, Li [1 ]
Mammen, Mathai [2 ]
McNamara, Alexander J. [3 ]
Mischki, Trevor K. [1 ]
Obedencio, Glenmar P. [3 ]
Pulido-Rios, Tess [3 ]
Steinfeld, Tod [2 ]
Sweazey, Shelley M. [3 ]
Wilson, Richard D. [1 ]
机构：
[1] Theravance Inc, Med Chem, San Francisco, CA 94080 USA
[2] Theravance Inc, Mol & Cellular Biol, San Francisco, CA 94080 USA
[3] Theravance Inc, Pharmacol, San Francisco, CA 94080 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 234卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
23-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Higher urge severity score predicts resumption of overactive bladder (OAB) medication following discontinuation of mirabegron treatment in patients with OAB
    Wang, Chung-Cheng
    Jiang, Yung-Hong
    Kuo, Hann-Chorng
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2019, 11 (02) : O180 - O185
  • [32] RELIABILITY AND VALIDITY OF THE OVERACTIVE BLADDER-PATIENT SATISFACTION WITH TREATMENT QUESTIONNAIRE (OAB-PSTQ)
    Sissins, Peter
    Barron, Richard L.
    QUALITY OF LIFE RESEARCH, 2005, 14 (09) : 2032 - 2032
  • [33] Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB)
    Mohee, Amar
    Khan, Ayisha
    Harris, Neil
    Eardley, Ian
    BJU INTERNATIONAL, 2013, 111 (01) : 106 - 113
  • [34] Flexible dose fesoterodine in the treatment of overactive bladder (OAB) (vol 112, pg 281, 2013)
    Tubaro, A.
    De Nunzio, C.
    BJU INTERNATIONAL, 2013, 112 (06) : E430 - E430
  • [35] SAFETY AND PERFORMANCE OF A WIRELESS IMPLANTABLE TIBIALNERVE STIMULATOR DEVICE, FOR THE TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)
    Heesakkers, J.
    van Breda, J.
    Van Kerrebroeck, P.
    Digesu, A.
    Elneil, S.
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S30 - S31
  • [36] EFFICACY AND SAFETY OF FESOTERODINE TREATMENT FOR OVERACTIVE BLADDER (OAB) SYMPTOMS IN ELDERLY WOMEN WITH AND WITHOUT HYPERTENSION
    Yoshida, M.
    Hotta, S.
    Hiro, S.
    Yamagami, H.
    Yokoyama, O.
    NEUROUROLOGY AND URODYNAMICS, 2016, 35 : S294 - S295
  • [37] Chapter 4: Guidelines for the Diagnosis and Treatment of Overactive Bladder (OAB) and Neurogenic Detrusor Overactivity (NDO)
    Nambiar, Arjun
    Lucas, Malcolm
    NEUROUROLOGY AND URODYNAMICS, 2014, 33 : S21 - S25
  • [38] Do we need more patient-friendly treatment options for overactive bladder (OAB)?
    Gerig, Nel
    Cameron, Tracy
    Arora, Samir
    Spear, Jessica
    Lescozec, Laura
    Zhang, Mingming
    NEUROUROLOGY AND URODYNAMICS, 2021, 40 (06) : 1433 - 1440
  • [39] Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study
    Chancellor, Michael B.
    Yehoshua, Alon
    Waweru, Catherine
    Globe, Denise
    Cheng, I-Ning
    Campbell, Karen L.
    Joshi, Manher
    Pulicharam, Riya
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2016, 48 (07) : 1029 - 1036
  • [40] Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study
    Michael B. Chancellor
    Alon Yehoshua
    Catherine Waweru
    Denise Globe
    I-Ning Cheng
    Karen L. Campbell
    Manher Joshi
    Riya Pulicharam
    International Urology and Nephrology, 2016, 48 : 1029 - 1036
12345